Further resources

27 June 2020

Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA trial

Kadowaki T et al. Diabetol Int 2020; doi: 10.1007/s13340-020-00447-5

[https://link.springer.com/article/10.1007/s13340-020-00447-5]

9 February 2020

Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: a prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA trial

Cooper ME et al. Diabetes Obes Metab 2020;22:1062

[https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.13995]

14 March 2018

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Rosenstock J et al. Cardiovasc Diabetol 2018;17:39

[https://cardiab.biomedcentral.com/articles/10.1186/s12933-018-0682-3]

©2020 Boehringer Ingelheim International GmbH. All rights reserved.